Find-A-Study

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Purpose

This is a 2-arm, Phase 3 study to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in Lung Subtype Panel (LSP) positive subjects with metastatic or advanced non-squamous non-small cell lung cancer.

Study Contact

Principal Investigator
Subrata Debnath

Subrata Debnath
(210) 508-2889
nath@uthscsa.edu

Eligibility

Eligible Ages: Between 18 Years and 99 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Purpose

Category

Study Contact

Eligibility

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups